Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (42408)	1/6/1999 12:47:00 PM
From: Michael Rich	Read Replies (1) \| Respond to of 132070

Thank you, MB. IMNX is THE best performing biotech stock 2 years in a row...and it is still hardly known by public.

To: Knighty Tin who wrote (42408)	1/6/1999 12:48:00 PM
From: upanddown	Read Replies (2) \| Respond to of 132070

Mike, article on Intel's rapidly eroding market share...love "bullish" comment from Intel exec about "free PC's" latimes.com; Intel's share of the U.S. retail market dropped to 55% in the fourth quarter of 1998, compared with 80% a year earlier, according to ZD Market Intelligence in San Diego. The world's largest chip maker enjoys a 60% share of the overall market for microprocessors designed to run computers that cost less than $1,000, but this is down from 68% nine months ago, according to Mercury Research in Scottsdale, Ariz. John

To: Knighty Tin who wrote (42408)	1/6/1999 2:43:00 PM
From: Ilaine	Read Replies (2) \| Respond to of 132070

Mike, the following questions are related to your discussion yesterday of your valuation model for biotechs: You stated that your valuation for Immunex was 5% more than $126. If the FDA were to approve Enbrel for other autoimmune diseases like scleroderma and lupus, would you change your valuation? I am assuming the answer is yes, so the real question is, would you change your valuation before approval, upon anticipation of approval, or after approval? If you were convinced that Enbrel would have uses other than rheumatoid arthritis, would it be foolish and/or speculative to buy in anticipation? BTW, I am not long IMNX, but am considering it. The closest competition to Enbrel, Arava, is having serious problems, IMHO.